血管紧张素Ⅱ2型受体基因多态性与钙拮抗剂降压效果相关性研究

目的：探讨山东地区原发性高血压患者血管紧张素Ⅱ2型受体基因A1675G多态性与钙拮抗剂降压效果的相关性。方法：对300例原发性高血压患者，用硝苯地平控释片进行为期8周的降压治疗，用PCR结合高分辨率溶解曲线、基因测序方法检测患者血管紧张素1I2型受体基因多态性。结果：257例患者完成试验，其中女127例，男130例。在女性患者中基因型AA、AG和GG收缩压和舒张压降压幅度及药物疗效方面差异均无统计学意义（P〉0．05），男性患者中基因型AA和GG在降压幅度及药物疗效方面差异亦无统计学意义（P〉0．05）。结论：在山东地区高血压患者中，A1675G多态性可能不会影响硝苯地平控释片降压效果。

Study on the relationship between the polymorphism of blocker

Objective To investigate the relationship between A1675G polymorphism of AT2 receptor gene and therapeutic effect of calcium chennel blocker in patients with essential hypertension in Shandong province. Methods Three hundred patients with essential hypertension were treated with Procardin for 8 weeks. The blood samples from the patients were collected to determine their AT2R gene polymorphism by PCR combined with HRM sequencing. Results The test was fulfilled in 257 patients, in which 127 were female and 130 were male. In the female patients, the therapeutic effect of Procardin among different AT2R genotypes and the decline of blood pressure showed no statistic difference（P〉0.05）. And in male patients, the therapeutic effect of Procardin among different AT2R genotypes and the decline of blood pressure showed no statistic difference（P〉0.05）. Conclusion The polymorphism of AT2R genotype may not influence the therapeutic effect of Procardin on hypertension in Shandong province.